## AZN: Astrazeneca PLC - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.9% below STRENGTH zone (3.0-6.0%); PEG 1.03 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($88.44)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Rexford Capital Inc. Invests $948,000 in AstraZeneca PLC $AZN**
- Source: MarketBeat | 20251214T111016 | Bullish | Relevance: 100%
- Rexford Capital Inc. initiated a new position in AstraZeneca PLC (NASDAQ:AZN) during the second quarter, purchasing 13,566 shares valued at approximately $948,000. Several other institutional investors also significantly increased their holdings in AstraZeneca. The company recently exceeded quarterly earnings expectations and holds a "Moderate Buy" consensus analyst rating with a target price of $95.75.

**2. AstraZeneca's Enhertu and Genentech's Perjeta combo gains breast cancer approval**
- Source: Seeking Alpha | 20251215T220918 | Bullish | Relevance: 100%
- The U.S. FDA has approved a combination therapy of AstraZeneca/Daiichi Sankyo's Enhertu and Roche-owned Genentech's Perjeta for the first-line treatment of HER2-positive breast cancer. This approval is based on phase 3 data indicating that the combination significantly reduced disease progression or death.

**3. Holocene Advisors LP Sells 124,752 Shares of AstraZeneca PLC $AZN**
- Source: MarketBeat | 20251214T131016 | Somewhat-Bullish | Relevance: 100%
- Holocene Advisors LP has reduced its stake in AstraZeneca PLC by selling 124,752 shares, bringing its total holdings to 4,321,629 shares valued at approximately $302 million. This move makes AstraZeneca the 26th-largest holding in the fund's portfolio, representing about 0.7% of its total assets. The company recently exceeded quarterly expectations with an EPS of $1.19 and revenue of $15.19 billion, while analysts currently rate AZN as a "Moderate Buy" with a target price of $95.75.

**4. AstraZeneca PLC $AZN Shares Bought by Cubist Systematic Strategies LLC**
- Source: MarketBeat | 20251213T111038 | Bullish | Relevance: 100%
- Cubist Systematic Strategies LLC significantly increased its stake in AstraZeneca PLC, purchasing an additional 249,364 shares in the second quarter, bringing its total holdings to 484,078 shares valued at $33.83 million. Other institutional investors also modified their positions in AZN. The pharmaceutical giant recently exceeded Q3 earnings estimates with EPS of $1.19 and revenue of $15.19 billion, and analysts currently rate the stock as a "Moderate Buy" with a consensus target price of $95.75.

**5. AstraZeneca, Daiichi's breast cancer drug gets FDA nod as first-line treatment**
- Source: Reuters | 20251216T010918 | Bullish | Relevance: 100%
- The U.S. Food and Drug Administration (FDA) has approved Enhertu, a breast cancer drug from AstraZeneca and Daiichi Sankyo, for first-line treatment in combination with Roche's Perjeta. This expanded approval targets adults with advanced HER2-positive breast cancer, based on study results showing a significant extension in progression-free survival. The decision moves Enhertu beyond its initial third-line treatment approval in 2019.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 10.3% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Price (T.Rowe) Assoc: 1.9% (-5.4%)
- Primecap Management : 1.5% (-3.3%)
- Bank of America Corp: 1.2% (+4.7%)
- Wellington Managemen: 1.2% (-5.9%)
- Capital Internationa: 0.9% (-20.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +5.2% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.03 suggests fair value with growth premium. Quality metrics strong (ROE 22%, margin 16%). Balance sheet: $4.4B free cash flow. Institutional flow bearish (6 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $283.9B |
| Beta | 0.17 |
| 52W Range | $61.24 - $94.02 |
| Short Interest | 0.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.03 |
| Forward P/E | 17.8 |
| Current P/E | 19.9 |
| YoY Growth | 12.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -2.3% to 2.9% (+5.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.1pp (needs >3.0% for momentum thesis). MRS_5 at 2.6% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 59. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.86% (CS: 60) | Neutral |
| RSI_14 | 58.7 | Neutral |
| MACD Histogram | -0.31 | Bearish |
| vs SMA20 | 1.009x | Above |
| vs SMA50 | 1.052x | Above |
| vs SMA200 | 1.191x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $91.56
- **Stop Loss:** $88.44 (3.4% risk)
- **Target:** $94.68 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 384
- **Position Value:** $35,159.04
- **Portfolio %:** 35.16%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-10 (Est: $1.09)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.13 | $1.19 | +4.9% |
| 2025Q2 | $1.46 | $1.08 | -25.9% |
| 2025Q1 | $1.12 | $1.25 | +11.6% |
| 2024Q4 | $1.04 | $1.04 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*